Skip to main content

Table 2 Treatment patterns of gastric or GEJ cancer patients receiving ramucirumab

From: Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices

Analysis variable Total study cohort (N = 505) Monotherapy subgroup (n = 115) Combination therapy subgroup (n = 390) P value
Regimen used for index, n (%)     
 Ramucirumab monotherapy 115 (22.77%)    
 Ramucirumab + paclitaxel 381 (75.45%)    
 Ramucirumab + other combination agents 9 (1.78%)    
Switched ramucirumab regimen, n (%)     
 Combination to monotherapy 4 (44.44%)    
 Monotherapy to combination 5 (55.56%)    
First LOT with ramucirumab, n (%)     < 0.0001a
 LOT1 15 (2.97%) 4 (3.48%) 11 (2.82%)  
 LOT2 407 (80.59%) 65 (56.52%) 342 (87.69%)
 LOT3 58 (11.49%) 31 (26.96%) 27 (6.92%)
 LOT4+ 18 (3.56%) 13 (11.30%) 5 (1.28%)
 LOT unknown 7 (1.39%) 2 (1.74%) 5 (1.28%)  
Duration of follow-up (months)     < 0.0001b
 Mean (SD) 11.13 (6.43) 8.77 (6.28) 11.83 (6.32)  
 Median (IQR) 9.86 (6.28,15.19) 6.90 (3.78,12.23) 10.64 (7.00,15.68)  
Treatment immediately following ramucirumab discontinuation, n (%)     
 Subsequent treatment 145 (28.71%) 35 (30.44%) 110 (28.21%) 0.6423c
 Anthracycline-containing 6 (1.19%) 1 (0.87%) 5 (1.28%) 1.000a
 Antineoplastic-containing 9 (1.78%) 4 (3.48%) 5 (1.28%) 0.1247a
 Trastuzumab-containing 17 (3.37%) 7 (6.09%) 10 (2.56%) 0.0657c
 Platinum-containing 23 (4.55%) 8 (6.96%) 15 (3.85%) 0.1598c
 Taxane-containing 23 (4.55%) 7 (6.09%) 16 (4.10%) 0.3697c
 Irinotecan-containing 41 (8.12%) 6 (5.22%) 35 (8.97%) 0.1949c
 Fluoropyrimidine-containing 51 (10.10%) 13 (11.30%) 38 (9.74%) 0.6254c
Duration of ramucirumab therapy (months)d     0.2378b
 Mean (SD) 3.13 (3.23) 2.91 (3.31) 3.20 (3.21)  
 Median (IQR) 2.10 (0.95,4.24) 1.87 (0.95,4.24) 2.30 (0.95,4.6)  
Number of ramucirumab infusions across all LOTs     0.6329b
 Patients with available data 511 117 394  
 Number of ramucirumab infusions 3507 791 2716  
 Mean (SD) 6.86 (6.11) 6.76 (6.69) 6.89 (5.94)  
 Median (IQR) 5 (3,9) 5 (3,7) 5 (3,10)  
LOT1     0.5109b
 Patients with available dataf 15 4 11  
 Number of ramucirumab infusions 83 22 61  
 Mean (SD) 5.53 (4.19) 5.50 (2.08) 5.55 (4.82)  
 Median (IQR) 5 (3,8) 5.5 (4,7) 4 (2,8)  
LOT2     0.4358b
 Patients with available dataf 408 65 343  
 Number of ramucirumab infusions 2898 500 2398  
 Mean (SD) 7.10 (6.33) 7.69 (7.62) 6.99 (6.07)  
 Median (IQR) 5 (3,10) 5 (4,8) 5 (3,10)  
LOT3     0.6567b
 Patients with available dataf 61 33 28  
 Number of ramucirumab infusions 366 200 166  
 Mean (SD) 6.00 (4.98) 6.06 (4.66) 5.93 (5.42)  
 Median (IQR) 5 (3,6) 5 (3,6) 4.5 (2.5,6.5)  
LOT4+     0.0190b
 Patients with available dataf 19 13 6  
 Number of ramucirumab infusions 104 64 40  
 Mean (SD) 5.47 (6.08) 4.92 (7.10) 6.67 (3.08)  
 Median (IQR) 4 (2,7) 2 (2,4) 6 (4,8)  
LOT Unknown     0.0651b
 Patients with available dataf 8 2 6  
 Number of ramucirumab infusions 56 5 51  
 Mean (SD) 7 (5.29) 2.50 (0.71) 8.50 (5.32)  
 Median (IQR) 4.5 (3,11.5) 2.5 (2,3) 7.5 (4,13)  
Ramucirumab dose modifications (cycles)e     0.2216b
 Patients with available data 14 2 12  
 Mean (SD) 3.29 (1.90) 5 (2.83) 3.00 (1.71)  
 Median (IQR) 3 (2,4) 5 (3,7) 3 (2,3.5)  
  1. aP value calculated based on a Fisher’s Exact test
  2. bP value calculated based on a Kruskal–Wallis test
  3. cP value calculated based on a χ2 test
  4. dPatients with ongoing treatment were censored for overall follow-up, duration of therapy and survival estimates. In total, 100 patients were censored due to ongoing treatment. Ongoing treatment was defined as a treatment administration between 5 May 2016 and 30 June 2016
  5. ePatients with ongoing treatment were not censored for calculations of the number of dose modifications or infusions
  6. Patients may have received ramucirumab in multiple LOTs